Jason Buhrman, M.D., Ph.D. v. University of Rochester

District Court, W.D. New York·Decided August 6, 2026·No. 6:24-cv-06029·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF NEW YORK _______________________________________

JASON BUHRMAN, M.D., Ph.D., DECISION AND ORDER Plaintiff, 24-CV-6029 FPG CDH v.

UNIVERSITY OF ROCHESTER,

Defendant _______________________________________

INTRODUCTION Plaintiff Jason Buhrman, M.D., Ph.D. (“Plaintiff”), claims that defendant the University of Rochester (“Defendant” or the “University”) discriminated against him due to a medical disability and retaliated against him for seeking reasonable accommodations and taking approved medical leave. (See Dkt. 1). Defendant denies these claims. (See Dkt. 10). Presently before the Court is Plaintiff’s motion to compel. (Dkt. 35). For the reasons that follow, Plaintiff’s motion to compel is granted in part and denied in part. FACTUAL BACKGROUND I. The Program In 2017, Plaintiff began a program at the University known as the American Board of Internal Medicine Research Pathway (the “Program”). (Dkt. 41-1 at ¶ 4). Plaintiff’s enrollment, employment, and participation in the Program were pursuant to a contract with the University that was renewed on a year-by-year basis. (Dkt. 1 at ¶¶ 25-26). The Program combines traditional medical residency training with fellowship research. (Dkt. 1 at ¶ 24). For Plaintiff, the residency training portion of the Program was in general internal medicine (“IM”), and the fellowship research portion of the

Program was in his chosen specialty of hematology and oncology (“HemeOnc”). (Id.; Dkt. 41-1 at ¶¶ 5,7). Whereas traditionally a trainee1 would spend three years in an IM residency, then sit for the general IM boards before moving onto a fellowship, the Program “essentially compress[es] the [IM] residency portion into two years.” (Dkt. 41-1 at ¶ 6). The parties present slightly different explanations of Plaintiff’s transition from the residency portion of the Program to the fellowship portion. According to Plaintiff,

the first two years of the Program consisted of IM residency, the third year was a combined IM residency and HemeOnc fellowship clinical training, and the fourth through seventh years consisted of the HemeOnc fellowship clinical and research training. (Dkt. 35-2 at 5; Dkt. 42 at 8). Defendant, however, states that Plaintiff was required to complete two years of IM residency, followed by 18 months of clinical training in HemeOnc and three years of research training—though, to become board

eligible in IM, Plaintiff was required to complete both the two years of IM residency and the 18 months of clinical training in the HemeOnc fellowship. (Dkt. 41-1 at ¶ 7). In other words, there is a factual dispute about whether Plaintiff’s third year in the Program was a combination of the final year of his IM residency and the first year of his HemeOnc fellowship, as Plaintiff asserts, or whether Plaintiff’s third year was

1 The Court uses the term “trainee” to refer collectively to residents and fellows. strictly the first year of his HemeOnc fellowship, albeit a component of becoming board eligible for IM, as Defendant represents. II. Trainee Evaluations

Each University department has its own Clinical Competency Committee (“CCC”) that conducts bi-annual reviews of its residents and fellows based on the department’s own training milestones and evaluation standards, which are established by the Accreditation Council for Graduate Medical Education (“ACGME”). (Dkt. 35-2 at 5; Dkt. 41-1 at ¶¶ 13-14). For each bi-annual review, the trainee receives two documents: (1) a CCC action plan and (2) an ACGME milestone evaluation. (Dkt. 35-2 at 5; Dkt. 41-1 at ¶ 16). For the ACGME milestone evaluation,

there are four possible ratings: Superior, Satisfactory, Conditional on Improvement, and Unsatisfactory. (Dkt. 41-1 at ¶ 23). Conditional on Improvement means the trainee “meets some developmental milestones but occasionally falls short of the expected level of development for this year of training.” (Id.). III. Plaintiff’s Performance in the Program According to Defendant, Plaintiff completed “two years of the IM residency

training component of the Program” and “[h]is record reveals no performance deficiencies.” (Id. at ¶ 19). However, Plaintiff then received a Conditional on Improvement rating on his year-end evaluation for his third year in the Program (2019-20). (Id. at ¶ 22; Dkt. 41-2). Plaintiff states that at the end of his third year, the University awarded him his “Certificate of Completion of the Internal Medicine Residency Training Program.” (Dkt. 1 at ¶ 32). During his fourth year in the Program (2020-21), Plaintiff was suspended from clinical responsibilities due to what Defendant describes as “his struggles with patient care and serious concerns about his ability to safely treat patients.” (Dkt. 41-

1 at ¶ 25). Plaintiff again received a Conditional on Improvement rating on his fourth- year year-end evaluation. (Id. at ¶ 26; Dkt. 41-5). At the start of his fifth year in the Program (2021-22), Plaintiff, after previously experiencing symptoms related to what was eventually diagnosed as liver failure, suffered a grand mal seizure and “was placed on medical, disability, and FMLA leave.” (Dtk. 35-2 at 5). Plaintiff returned to the Program in January of 2022, when he again received a Conditional on Improvement rating on his fifth-year mid-

year evaluation. (Dkt. 41-1 at ¶¶ 28-29; see Dkt. 41-6). Plaintiff received a liver transplant in May of 2022. (Dkt. 1 at ¶ 59). At the end of his fifth year in the Program, the University decided not to offer Plaintiff a contract for his sixth year. (Dkt. 41-1 at ¶ 34). PROCEDURAL BACKGROUND This case has been referred to the undersigned for all non-dispositive pretrial

matters. (Dkt. 13; Dkt. 22). Plaintiff commenced this action on January 11, 2024, asserting federal and state law claims of discrimination and retaliation based on medical disability, as well as breach of contract. (Dkt. 1). Defendant filed an answer, asserting as its sixth affirmative defense that “[a]ny employment action taken by the University toward Plaintiff was taken for legitimate, non-discriminatory reasons,” and asserting as its seventh affirmative defense that “[a]t no time did the University take any action toward Plaintiff that it would not have taken toward similarly situated individuals regardless of disability.” (Dkt. 10 at ¶¶ 148-49). Plaintiff states that “[b]ased upon

the University’s Answer, written discovery responses, and deposition testimony, it has become clear that the University’s affirmative defenses are based on its contention that Dr. Buhrman was not satisfactorily performing in the Program.” (Dkt. 35-2 at 6). During the course of discovery, Plaintiff requested records related to other trainees at the University. (Dkt. 35-1 at ¶ 10). Defendant largely objected to these requests for production (“RFPs”) as overbroad, unduly burdensome, not relevant, and

disproportionate to the needs of the case, and refused to produce the requested documents. (Dkt. 35-1 at ¶ 11; Dkt. 35-11; Dkt. 35-12). For some documents that were produced, including HemeOnc CCC meeting notes, Defendant made extensive redactions, claiming that the redacted information was irrelevant or non-responsive. (Dkt. 35-1 at ¶ 12; Dkt. 35-13 at 4; Dkt. 35-14). After exchanging further correspondence with Defendant, Plaintiff submitted

Free access — add to your briefcase to read the full text and ask questions with AI

Jason Buhrman, M.D., Ph.D. v. University of Rochester, (W.D.N.Y. 2026).

Jason Buhrman, M.D., Ph.D. v. University of Rochester (Jason Buhrman, M.D., Ph.D. v. University of Rochester) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Oppenheimer Fund, Inc. v. Sanders
437 U.S. 340 (Supreme Court, 1978)
Ruiz v. County of Rockland
609 F.3d 486 (Second Circuit, 2010)
Christopher Graham v. Long Island Rail Road
230 F.3d 34 (Second Circuit, 2000)
Chen-Oster v. Goldman, Sachs & Co.
293 F.R.D. 557 (S.D. New York, 2013)